Published: Jun, 2017
A recent study by Transparency Market Research (TMR) has detected that the global radiopharmaceuticals market is consolidated in nature with two companies, GE Healthcare and Siemens Healthineers, holding 70% of the market in 2015. Radiopharmaceuticals make for an evolving market, which is attracting a number of other leading pharmaceutical players with technological capabilities and high production capacity. As a result, the competition is expected to get even stiffer in the near future.
The TMR report projects the global market for radiopharmaceuticals to increment demand at a CAGR of 5.3% during the forecast period of 2016 to 2024. According to the evaluations of the report, the global radiopharmaceuticals market was worth US$4.7 bn in 2015, and estimates it to reach a valuation of US$7.4 bn by the end of 2024.
Acquisition of niche players is the primary strategy adopted by these leading players to expand their geographical presence, while adopting new methods of production and robust sales support are other modes of maintain their stronghold over the market. For instance, AAA acquired GE Healthcare S.r.L’s FDG-PET business recently, after gaining full shares in Imaging Equipment Ltd. (IEL) in 2014. With these moves, the company has significantly strengthened their presence in the U.K., Italy, and Ireland.
Technetium-99 Most Profitable Radioisotope Segment
On the basis of source, the report segments the global radiopharmaceutical market into nuclear reactors and cyclotrons, and rates the former as slightly more profitable market segment than the latter. End-users of radiopharmaceutical market analyzed under this report are hospitals, diagnostic centers, ambulatory surgical centers, and others. Hospitals continue to serve significantly more demand, although technological advancements is poised to increment ambulatory surgical centers segment quickly during the forecast period.
On the basis of radioisotope, the report categorizes the global radiopharmaceutical market into technetium-99, iodine-123, 18F, gallium-67, yttrium-90, rubidium-82, and lutetium-177. Among these, technetium-99 accounted for 50.3% of the demand in 2016, although the report projects 18F segment to exhibit the most prominent CAGR of 5.5% during the forecast period of 2016 to 2024. Application-wise, the report rates oncology as most profitable, while the segments of cardiology, immunology, and nephrology are also poised for healthy growth in the near future.
Currently, North America is the most lucrative region for the vendors operating in the global radiopharmaceutical market, which is a reflection of robust healthcare infrastructure in developed countries such as the U.S. and Canada. Owing to increasing number of cyclotron installations to produce radioisotopes for the treatment of cancer, Europe is also expected to serve significant demand in the global radiopharmaceutical market during the forecast period. However, Asia Pacific is also expected to turn into a profitable market for the early investors, as countries such as India and China are among the fastest growing economies and are actively improving their healthcare facilities. Commitment to technology for the development of new therapeutic isotopes, growing research and development interest in nuclear medicine, and rapid urbanization are some of the other factors favoring the Asia
Pacific radiopharmaceutical market.
Prevalence of Cancer Driving Demand
Some of the key factors driving the global radiopharmaceutical market are: continued preference of radioisotopes for the diagnostic imaging, glaring benefits such as targeted therapeutic irradiation that have fewer side effects, easy detection of metastatic sites, positron emission tomography (PET), prevalence of cancer, and growing number of diagnostic, chemotherapy, and screen centers. On the other hand, strict regulations pertaining to the production and storage of radiopharmaceuticals is hindering the market for radiopharmaceutical from attaining its full potential.
The information presented in this review is based on a Transparency Market Research report, titled, “Radiopharmaceutical Market (Radioisotope - Technetium-99, Gallium-67, Iodine-123, 18F, Rubidium-82, Yttrium-90, and Lutetium-177; End User - Hospitals, Ambulatory Surgical Centers, and Diagnostic Centers; Source - Nuclear Reactor and Cyclotrons; Application - Cardiology, Gastroenterology, Oncology (Brachytherapy), Nephrology, Neurology, and Immunology) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024”
Key Segments of the Global Pharmaceutical Market
Global Radiopharmaceutical Market, by Radioisotope
Global Radiopharmaceutical Market, by Source
- Nuclear Reactors
Global Radiopharmaceutical Market, by End User
- Ambulatory Surgical Centers
- Diagnostic Centers
Global Radiopharmaceutical Market, by Application
Global Radiopharmaceutical Market, by Region
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453